NASDAQ:AGEN - Agenus Stock Price, Price Target & More

$3.60 +0.02 (+0.56 %)

(As of 04/24/2018 04:00 PM ET)

Previous Close$3.58

Today's Range$3.50 - $3.69

52-Week Range$3.24 - $6.19

Volume1.11 million shs

Average Volume1.63 million shs

Market Capitalization$387.67 million

P/E Ratio-2.95

Dividend YieldN/A

Beta1.66

About Agenus (NASDAQ:AGEN)

Agenus Inc., a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Receive AGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for AGEN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:AGEN

CUSIP00847G70

Webwww.agenusbio.com

Phone781-674-4400

Debt

Debt-to-Equity Ratio-1.88%

Current Ratio1.30%

Quick Ratio1.30%

Price-To-Earnings

Trailing P/E Ratio-2.95

Forward P/E Ratio-2.37

P/E GrowthN/A

Sales & Book Value

Annual Sales$42.88 million

Price / Sales8.61

Cash FlowN/A

Price / CashN/A

Book Value($0.74) per share

Price / Book-4.86

Profitability

EPS (Most Recent Fiscal Year)($1.23)

Net Income$-120,690,000.00

Net Margins-281.49%

Return on EquityN/A

Return on Assets-72.33%

Miscellaneous

Employees255

Outstanding Shares102,560,000

How to Become a New Pot Stock Millionaire

Agenus (NASDAQ:AGEN) Frequently Asked Questions

What is Agenus' stock symbol?

Agenus trades on the NASDAQ under the ticker symbol "AGEN."

How were Agenus' earnings last quarter?

Agenus (NASDAQ:AGEN) issued its quarterly earnings results on Thursday, March, 15th. The biotechnology company reported ($0.35) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.28) by $0.07. The biotechnology company earned $8.30 million during the quarter, compared to analyst estimates of $5.30 million. The business's revenue for the quarter was up 48.2% on a year-over-year basis. View Agenus' Earnings History.

When is Agenus' next earnings date?

Agenus is scheduled to release their next quarterly earnings announcement on Thursday, May, 3rd 2018. View Earnings Estimates for Agenus.

What price target have analysts set for AGEN?

2 brokerages have issued 12-month price targets for Agenus' stock. Their forecasts range from $5.00 to $7.00. On average, they expect Agenus' stock price to reach $6.00 in the next twelve months. View Analyst Ratings for Agenus.

Who are some of Agenus' key competitors?

Some companies that are related to Agenus include Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Iovance Biotherapeutics (IOVA), REGENXBIO (RGNX), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP), Acorda Therapeutics (ACOR), Bavarian Nordic (BVNRY), La Jolla Pharmaceutical (LJPC), Coherus BioSciences (CHRS), Novavax (NVAX), Jounce Therapeutics (JNCE), Heska (HSKA) and Voyager Therapeutics (VYGR).

Who are Agenus' key executives?

Agenus' management team includes the folowing people:

Dr. Garo H. Armen Ph.D., Founder, Exec. Chairman & CEO (Age 65)
Ms. Christine M. Klaskin, VP of Fin. (Age 52)
Ms. Karen Higgins Valentine, Chief Legal Officer & Gen. Counsel (Age 46)
Mr. Ozer Baysal, Chief Commercial Officer & Head of HR (Age 62)
Dr. Robert B. Stein Ph.D., M.D., Sr. R&D Advisor (Age 67)

Has Agenus been receiving favorable news coverage?

Press coverage about AGEN stock has been trending somewhat positive on Tuesday, according to Accern. Accern scores the sentiment of media coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Agenus earned a media sentiment score of 0.24 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 46.05 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.

How do I buy shares of Agenus?

Shares of AGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Agenus' stock price today?

One share of AGEN stock can currently be purchased for approximately $3.60.

How big of a company is Agenus?

Agenus has a market capitalization of $387.67 million and generates $42.88 million in revenue each year. The biotechnology company earns $-120,690,000.00 in net income (profit) each year or ($1.23) on an earnings per share basis. Agenus employs 255 workers across the globe.

How can I contact Agenus?

Agenus' mailing address is 3 FORBES ROAD, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-674-4400 or via email at [email protected]

MarketBeat Community Rating for Agenus (AGEN)

Community Ranking:		3.0 out of 5 ( )
Outperform Votes:		278 (Vote Outperform)
Underperform Votes:		190 (Vote Underperform)
Total Votes:		468

MarketBeat's community ratings are surveys of what our community members think about Agenus and other stocks. Vote "Outperform" if you believe AGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Agenus (NASDAQ:AGEN) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

2 Wall Street analysts have issued ratings and price targets for Agenus in the last 12 months. Their average twelve-month price target is $6.00, suggesting that the stock has a possible upside of 66.67%. The high price target for AGEN is $7.00 and the low price target for AGEN is $5.00. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.50	2.67	2.67	2.75
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 2 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 3 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$6.00	$6.3333	$6.3333	$6.3333
Price Target Upside:	66.67% upside	57.55% upside	57.55% upside	57.55% upside

Agenus (NASDAQ:AGEN) Consensus Price Target History

Price Target History for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/4/2017	Jefferies Group	Reiterated Rating	Buy	$7.00	High
5/6/2017	HC Wainwright	Set Price Target	Hold	$5.00	Low
4/23/2017	Maxim Group	Reiterated Rating	Buy	$7.00	Medium
12/1/2016	JMP Securities	Reiterated Rating	Buy		N/A

(Data available from 4/24/2016 forward)

Agenus (NASDAQ:AGEN) Earnings History and Estimates Chart

Earnings by Quarter for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ:AGEN) Earnings Estimates

2018 EPS Consensus Estimate: ($1.36)
2019 EPS Consensus Estimate: ($1.39)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.35)	($0.35)	($0.35)
Q2 2018	1	($0.34)	($0.34)	($0.34)
Q3 2018	1	($0.33)	($0.33)	($0.33)
Q4 2018	1	($0.34)	($0.34)	($0.34)
Q1 2019	1	($0.35)	($0.35)	($0.35)
Q2 2019	1	($0.35)	($0.35)	($0.35)
Q3 2019	1	($0.35)	($0.35)	($0.35)
Q4 2019	1	($0.34)	($0.34)	($0.34)

Agenus (NASDAQ AGEN) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/3/2018
3/15/2018	Q4 2017	($0.28)	($0.35)	$5.30 million	$8.30 million	View	Listen
11/7/2017	Q3	($0.37)	($0.37)	$5.91 million	$3.40 million	View	N/A
8/3/2017	Q2 2017	($0.36)	($0.32)	$6.66 million	$4.21 million	View	Listen
5/4/2017	Q1 2017	($0.32)	($0.18)	$5.22 million	$26.96 million	View	Listen
3/9/2017	Q4 2016	($0.30)	($0.30)	$6.01 million	$5.58 million	View	Listen
10/27/2016	Q316	($0.32)	($0.47)	$6.15 million	$4.45 million	View	Listen
7/28/2016	Q216	($0.34)	($0.33)	$5.12 million	$6.59 million	View	Listen
4/28/2016	Q116	($0.23)	($0.37)	$6.74 million	$5.96 million	View	Listen
3/3/2016	Q415	($0.17)	($0.18)	$9.39 million	$7.64 million	View	Listen
10/27/2015	Q315	($0.15)	($0.16)	$5.71 million	$6.85 million	View	Listen
7/23/2015	Q215	($0.15)	($0.44)	$5.71 million	$6.38 million	View	Listen
4/23/2015	Q115	($0.15)	($0.21)	$11.66 million	$3.95 million	View	N/A
2/26/2015	Q414	($0.15)	($0.18)	$0.66 million	$1.62 million	View	N/A
10/31/2014	Q314	($0.15)	($0.13)	$1.96 million	$1.56 million	View	N/A
7/24/2014	Q214	($0.11)	($0.12)	$0.71 million	$3.07 million	View	N/A
5/8/2014	Q114	($0.16)	$0.01	$0.55 million	$0.7210 million	View	N/A
3/5/2014	Q413	($0.24)	($0.16)	$870.00 million	$393.00 million	View	N/A
10/24/2013	Q313	($0.27)	($0.24)		$736.00 million	View	N/A
7/25/2013	Q2 2013	($0.21)	($0.40)	$1.18 million	$0.81 million	View	N/A
4/24/2013	Q1 2013	($0.19)	($0.35)	$1.13 million	$1.11 million	View	N/A
2/28/2013	Q4 2012	($0.24)	($0.23)	$0.72 million	$1.09 million	View	N/A
10/25/2012	Q3 2012	($0.28)	($0.24)			View	N/A
8/2/2012	Q2 2012	($0.26)	($0.31)			View	N/A
4/25/2012	Q1 2012	($0.29)	$0.29			View	N/A
3/5/2012	Q4 2011	($0.28)	($0.29)			View	N/A
10/27/2011	Q3 2011	($0.27)	($0.28)			View	N/A
7/28/2011		($0.05)	($0.05)			View	N/A
4/28/2011	Q1 2011	($0.24)	($0.30)			View	N/A
2/17/2011	Q4 2010	($0.30)	($0.18)			View	N/A
10/28/2010	Q3 2010	($0.36)	($0.36)			View	N/A
7/29/2010	Q2 2010	($0.30)	($0.32)			View	N/A
4/29/2010	Q1 2010	($0.36)	($0.59)			View	N/A
2/18/2010	Q4 2009	($0.54)	$0.11			View	N/A
10/29/2009	Q3 2009	($0.66)	($0.76)			View	N/A
7/30/2009	Q2 2009	($0.78)	($1.02)			View	N/A
5/7/2009	Q1 2009	($0.72)	($0.87)			View	N/A
2/19/2009	Q4 2008	($0.96)	($0.65)			View	N/A
11/5/2008	Q3 2008	($1.08)	($1.01)			View	N/A
7/31/2008	Q2 2008	($1.08)	($1.13)			View	N/A
5/1/2008	Q1 2008	($0.84)	($1.21)			View	N/A
2/21/2008	Q4 2007	($1.38)	($0.97)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Agenus (NASDAQ:AGEN) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Agenus (NASDAQ AGEN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.90%
Institutional Ownership Percentage: 36.50%

Insider Trading History for Agenus (NASDAQ:AGEN)

Institutional Ownership by Quarter for Agenus (NASDAQ:AGEN)

Agenus (NASDAQ AGEN) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/12/2017	Alex Duncan	CTO	Sell	6,546	$3.46	$22,649.16	27,572
12/12/2017	Christine M Klaskin	VP	Sell	5,610	$3.46	$19,410.60	69,943
12/12/2017	Karen Valentine	Insider	Sell	8,358	$3.46	$28,918.68	109,879
10/30/2017	Garo H Armen	CEO	Buy	100,000	$3.55	$355,000.00
4/12/2017	Garo H Armen	CEO	Buy	100,000	$3.35	$335,000.00	1,389,021
2/14/2017	Corp Incyte	Major Shareholder	Buy	10,000,000	$6.00	$60,000,000.00	17,763,968
9/6/2016	Ulf Wiinberg	Director	Buy	30,000	$6.29	$188,700.00	30,000
5/9/2016	Garo H Armen	CEO	Buy	100,000	$3.18	$318,000.00	1,346,026
5/5/2016	Ozer Baysal	Insider	Buy	2,250	$3.10	$6,975.00	33,538
3/7/2016	Garo H Armen	CEO	Buy	200,000	$4.03	$806,000.00	1,251,228
12/29/2015	Garo H. Armen	CEO	Sell	219,576	$4.59	$1,007,853.84	1,051,228
12/28/2015	Garo H. Armen	CEO	Sell	134,352	$4.60	$618,019.20	1,051,228
9/25/2015	Charles Evan Ballantyne	CFO	Buy	10,000	$5.05	$50,500.00	10,000
9/25/2015	Garo H Armen	CEO	Buy	100,000	$5.03	$503,000.00	1,409,607
4/29/2015	Shahzad Malik	Director	Sell	1,107,377	$7.11	$7,873,450.47
1/9/2015	Qvt Associates Gp Llc	Major Shareholder	Sell	2,343,630	$5.31	$12,444,675.30
1/23/2014	Karen Valentine	VP	Sell	2,850	$3.50	$9,975.00	51,534

(Data available from 1/1/2013 forward)

Agenus (NASDAQ AGEN) News Headlines

Source:

Date	Headline
	$16.39 Million in Sales Expected for Agenus Inc (AGEN) This Quarter www.americanbankingnews.com - April 20 at 4:28 AM
	Agenus (AGEN) Downgraded by ValuEngine to Sell www.americanbankingnews.com - April 18 at 11:22 PM
	Brokerages Expect Agenus Inc (AGEN) to Announce -$0.28 Earnings Per Share www.americanbankingnews.com - April 18 at 8:13 AM
	Agenus (AGEN) Rating Increased to Buy at BidaskClub www.americanbankingnews.com - April 16 at 7:35 PM
	Agenus (AGEN) Upgraded to Sell by ValuEngine www.americanbankingnews.com - April 16 at 7:34 PM
	Why Is Agenus (AGEN) Down 17.7% Since its Last Earnings Report? finance.yahoo.com - April 16 at 8:49 AM
	Agenus (AGEN) Downgraded to Hold at BidaskClub www.americanbankingnews.com - April 14 at 8:31 AM
	Three Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 ... www.prnewswire.com - April 11 at 4:59 PM
	Will Agenus Inc’s (NASDAQ:AGEN) Earnings Grow Over The Next Few Years? finance.yahoo.com - April 11 at 4:59 PM
	Three Agenus Abstracts Accepted for Presentation at the American Association for Cancer Research (AACR) 2018 Annual Meeting finance.yahoo.com - April 11 at 4:59 PM
	Agenus Inc (AGEN) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - April 11 at 1:24 AM
	Agenus (AGEN) Rating Lowered to Strong Sell at BidaskClub www.americanbankingnews.com - April 7 at 7:02 AM
	-$0.28 Earnings Per Share Expected for Agenus Inc (AGEN) This Quarter www.americanbankingnews.com - April 1 at 7:23 AM
	Agenus (AGEN) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - March 30 at 11:10 PM
	Agenus (AGEN) Stock Rating Upgraded by Zacks Investment Research www.americanbankingnews.com - March 29 at 11:18 PM
	Agenus (AGEN) Rating Lowered to Sell at BidaskClub www.americanbankingnews.com - March 29 at 11:16 AM
	Agenus to Present at Healthcare Investor Conferences In April finance.yahoo.com - March 29 at 9:07 AM
	Agenus (AGEN) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - March 28 at 12:58 PM
	Agenus (AGEN) Upgraded by BidaskClub to Buy www.americanbankingnews.com - March 24 at 4:30 PM
	Agenus (AGEN) Lowered to Sell at Zacks Investment Research www.americanbankingnews.com - March 20 at 1:16 PM
	Brokers Issue Forecasts for Agenus Inc's FY2022 Earnings (AGEN) www.americanbankingnews.com - March 19 at 10:02 AM
	Agenus Inc (AGEN) Expected to Post Q1 2019 Earnings of ($0.35) Per Share www.americanbankingnews.com - March 19 at 6:46 AM
	BidaskClub Downgrades Agenus (AGEN) to Buy www.americanbankingnews.com - March 18 at 7:10 PM
	Edited Transcript of AGEN earnings conference call or presentation 15-Mar-18 3:00pm GMT finance.yahoo.com - March 18 at 8:50 AM
	Agenus Inc (AGEN) Given Average Recommendation of "Buy" by Brokerages www.americanbankingnews.com - March 17 at 1:36 AM
	Agenus Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update finance.yahoo.com - March 15 at 5:33 PM
	Agenus (AGEN) Reports Wider than Expected Q4 Loss, Sales Miss finance.yahoo.com - March 15 at 5:33 PM
	Agenus (AGEN) Posts Earnings Results, Misses Expectations By $0.07 EPS www.americanbankingnews.com - March 15 at 9:40 AM
	Agenus report Q4 results; shares down 4% premarket seekingalpha.com - March 15 at 9:18 AM
	Agenus Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update - PR Newswire (press release) www.prnewswire.com - March 15 at 8:48 AM
	What's Happening with These Biotech Stocks? -- Aeterna Zentaris, Affimed, Agenus, and Agios Pharma www.bizjournals.com - March 13 at 9:03 AM
	Agenus (AGEN) Upgraded at BidaskClub www.americanbankingnews.com - March 11 at 7:10 PM
	Agenus (AGEN) to Release Earnings on Thursday www.americanbankingnews.com - March 8 at 9:58 AM
	Steven Cohen Takes Stake in Biotech Company Agenus finance.yahoo.com - March 7 at 5:53 PM
	Agenus to Report Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 and Host Conference Call ... - PR Newswire (press release) www.prnewswire.com - March 7 at 8:59 AM
	Agenus to Report Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 and Host Conference Call and Webcast finance.yahoo.com - March 7 at 8:59 AM
	Has Agenus Inc (NASDAQ:AGEN) Improved Earnings Growth In Recent Times? finance.yahoo.com - March 6 at 5:15 PM
	Hudson Bay Capital Management LP Acquires 170,000 Shares of Agenus Inc (AGEN) www.americanbankingnews.com - March 2 at 1:32 PM
	Brokerages Expect Agenus Inc (AGEN) Will Announce Quarterly Sales of $15.58 Million www.americanbankingnews.com - February 28 at 1:50 PM
	Analysts Expect Agenus Inc (AGEN) Will Post Earnings of -$0.28 Per Share www.americanbankingnews.com - February 26 at 5:15 AM
	Agenus (AGEN) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - February 23 at 10:52 PM
	What's in Store for Agenus (AGEN) This Earnings Season? finance.yahoo.com - February 21 at 5:05 PM
	Why Agenus Stock Spiked Tuesday finance.yahoo.com - February 21 at 8:53 AM
	Global Blood Therapeutics (GBT) versus Agenus (AGEN) Financial Review www.americanbankingnews.com - February 20 at 5:34 PM
	Agenus: Positioned To Rapidly Enhance Shareholder Value seekingalpha.com - February 20 at 8:42 AM
	Agenus Inc (AGEN) Receives Consensus Recommendation of "Hold" from Analysts www.americanbankingnews.com - February 20 at 1:36 AM
	Agenus (AGEN) Upgraded by BidaskClub to Hold www.americanbankingnews.com - February 17 at 1:40 PM
	Are Options Traders Betting on a Big Move in Agenus (AGEN) Stock? www.msn.com - February 13 at 9:39 AM
	Is Agenus Inc. a Buy? www.fool.com - February 13 at 8:16 AM
	Agenus (AGEN) Raised to "Sell" at BidaskClub www.americanbankingnews.com - February 11 at 8:54 AM

Agenus (NASDAQ:AGEN) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Agenus (NASDAQ:AGEN) Income Statement, Balance Sheet and Cash Flow Statement

Agenus (NASDAQ AGEN) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff